https://scholars.lib.ntu.edu.tw/handle/123456789/458595
標題: | Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation | 作者: | Kwak E.L. Shapiro G.I. Cohen S.M. Becerra C.R. Lenz H.-J. WEN-FANG CHENG Su W.-C. Robohn M. Le Maulf F. Lobmeyer M.T. Chand V.K. Iafrate A.J. |
公開日期: | 2013 | 卷: | 119 | 期: | 16 | 起(迄)頁: | 3043-3051 | 來源出版物: | Cancer | 摘要: | BACKGROUND The efficacy of afatinib, an irreversible ErbB Family Blocker, was evaluated in patients who had 1 of 4 categories of solid tumors with epidermal growth factor receptor/human epidermal growth factor receptor 2 (EGFR/HER2) gene amplification or EGFR-activating mutations. METHODS Patients with previously treated but ErbB inhibitor-naive esophagogastric, biliary tract, urothelial tract, or gynecologic cancers (lung cancers were excluded) harboring EGFR/HER2 gene amplification or high polysomy were identified by fluorescence in situ hybridization (FISH). Tumors were also screened for EGFR mutations. The primary endpoint was the objective response rate; secondary endpoints included the clinical benefit rate, pharmacokinetics, and safety. RESULTS Of 385 prescreened patients, 38 had FISH-positive tumors (10 with EGFR amplification and 29 with HER2 amplification or high polysomy [1 tumor had EGFR/HER2 high polysomy]; none had EGFR-activating mutations), and 20 patients received treatment with afatinib 50 mg daily. The objective response rate was 5% (1 of 20 patients), and the best objective response included 1 complete response. Eight patients experienced stable disease. The most frequently reported adverse events were diarrhea, rash, and decreased appetite. The trial closed early because of slow recruitment. CONCLUSIONS Single-agent afatinib activity was limited, yet encouraging, in selected tumors that were screened prospectively for target activation. The implementation of a biomarker-driven approach using a low-frequency biomarker for patient selection across multiple tumor types can be challenging. ? 2013 American Cancer Society. |
URI: | 2-s2.0-84881477255 https://scholars.lib.ntu.edu.tw/handle/123456789/458595 |
ISSN: | 0008-543X | DOI: | 10.1002/cncr.28120 | SDG/關鍵字: | afatinib; alkaline phosphatase; aspartate aminotransferase; creatinine; epidermal growth factor receptor; epidermal growth factor receptor 2; adult; aged; alkaline phosphatase blood level; alopecia; anemia; antineoplastic activity; article; backache; bacteremia; biliary tract cancer; cancer control; cancer growth; cancer patient; cancer screening; chemotherapy induced emesis; constipation; coughing; creatinine blood level; decreased appetite; dehydration; dermatitis; dermatitis acneiform; diarrhea; dizziness; drug blood level; drug dose reduction; drug eruption; drug safety; drug targeting; dry skin; dysgeusia; dyspepsia; dyspnea; EGFR gene; epistaxis; Escherichia coli infection; esophagus cancer; fatigue; female; female genital tract fistula; fistula; fluorescence in situ hybridization; gene activation; gene amplification; gene mutation; gene targeting; genetic screening; gynecologic cancer; hematuria; HER2 gene; human; hyperbilirubinemia; hypokalemia; hypomagnesemia; hyponatremia; hypotension; insomnia; major clinical study; male; monotherapy; multicenter study; multiple cycle treatment; muscle spasm; musculoskeletal pain; nausea; open study; paronychia; pelvis pain syndrome; peripheral edema; phase 2 clinical trial; pleura effusion; polysome; priority journal; protein family; pruritus; rhinorrhea; side effect; solid tumor; stomach cancer; stomatitis; thorax pain; treatment response; urinary tract infection; urogenital tract cancer; weight reduction |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。